JO
OVID icon

John Overdeck’s Ovid Therapeutics OVID Stock Holding History

John Overdeck’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Sell
832,378
-424,491
-34% -$1.1M ﹤0.01% 2899
2026
Q1 		$2.79M Buy
1,256,869
+658,000
+110% +$1.18M ﹤0.01% 2492
2025
Q4 		$976K Buy
598,869
+257,735
+76% +$397K ﹤0.01% 2931
2025
Q3 		$443K Buy
+341,134
New +$296K ﹤0.01% 3034
2024
Q3 		– Sell
-12,628
Closed -$9.71K – 3280
2024
Q2 		$9.71K Sell
12,628
-28,041
-69% -$78K ﹤0.01% 2961
2024
Q1 		$124K Buy
+40,669
New +$136K ﹤0.01% 2804
2021
Q3 		– Sell
-288,780
Closed -$1.13M – 4577
2021
Q2 		$1.13M Buy
+288,780
New +$1.14M ﹤0.01% 2373
2021
Q1 		– Sell
-345,706
Closed -$799K – 4147
2020
Q4 		$799K Buy
345,706
+25,441
+8% +$119K ﹤0.01% 2175
2020
Q3 		$1.84M Buy
+320,265
New +$2.14M 0.01% 1348
2020
Q2 		– Sell
-31,012
Closed -$92K – 3371
2020
Q1 		$92K Sell
31,012
-137,590
-82% -$464K ﹤0.01% 2857
2019
Q4 		$700K Buy
+168,602
New +$532K ﹤0.01% 2520
2019
Q3 		– Sell
-10,352
Closed -$19K – 3714
2019
Q2 		$19K Sell
10,352
-32,008
-76% -$57.2K ﹤0.01% 3260
2019
Q1 		$75K Sell
42,360
-4,903
-10% -$12.3K ﹤0.01% 2923
2018
Q4 		$114K Buy
+47,263
New +$216K ﹤0.01% 2798

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

John Overdeck's OVID Position: Q2 2026 in Review

John Overdeck reduced its Ovid Therapeutics (OVID) stake by 34% in Q2 2026, selling an estimated $1.1M and leaving 832,378 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

John Overdeck first reported a position in OVID in Q4 2018 and has held it in 14 quarters since. The position peaked at $2.79M in Q1 2026. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • John Overdeck held 832,378 shares of Ovid Therapeutics worth $2.24M as of Q2 2026.
  • John Overdeck sold 424,491 Ovid Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Ovid Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2899 holding.
  • John Overdeck first reported a position in Ovid Therapeutics in Q4 2018 and has held it in 14 quarters since.
  • John Overdeck's Ovid Therapeutics position peaked at $2.79M in Q1 2026.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.